Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?

被引:14
作者
Boerner, Thomas [1 ]
Roche, Kara Long [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Weill Cornell Med Coll, Dept Obstet & Gynecol, New York, NY USA
基金
美国国家卫生研究院;
关键词
Ovarian cancer; Salpingectomy; Risk-reducing surgery; Delayed oophorectomy; High-grade serous cancer; QUALITY-OF-LIFE; DELAYED OOPHORECTOMY; OPPORTUNISTIC SALPINGECTOMY; PROPHYLACTIC SALPINGECTOMY; BRCA2; MUTATIONS; REDUCING SURGERY; WOMEN; MULTICENTER; BREAST; CARRIERS;
D O I
10.1016/j.jmig.2020.09.020
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To summarize published evidence supporting current strategies for the prevention of epithelial ovarian cancer in women with a genetic, elevated risk for the development of this disease, as well as the emerging data on the novel salpingectomy with delayed oophorectomy (SDO) strategy. Furthermore, we will explore whether salpingectomy alone is a viable risk-reducing strategy for these women. We will also discuss current national guidelines for risk-reducing surgery based on patients' individual genetic predisposition. Data Sources: MEDLINE, PubMed, EMBASE, and the Cochrane Database, with a focus on randomized controlled trials and large prospective, observational studies. Methods of Study Selection: The key search terms for our review included Medical Subject Headings: "salpingectomy," "ovarian cancer," and "risk-reducing surgery." Tabulation, Integration, and Results: The fallopian tube is now well established as the site of origin for most ovarian cancers, particularly high-grade serous carcinomas. This finding has led to the development of new preventive surgical techniques, such as SDO, which may be associated with fewer side effects. However, until the results of ongoing trials are reported and the impact of SDO on ovarian cancer risk reduction is established, it should not be recommended outside of clinical trials, and bilateral salpingo-oophorectomy remains the treatment of choice for risk-reducing surgery, especially in women with a genetic, high risk for ovarian cancer. Conclusion: The decision to undergo risk-reducing surgery among women with an elevated risk for ovarian cancer should be made after comprehensive consultation and individually based on genetic predisposition, childbearing status, and personal preference. (C) 2020 AAGL. All rights reserved.
引用
收藏
页码:403 / 408
页数:6
相关论文
共 47 条
  • [1] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [2] Vasomotor flushes in menopausal women
    Bachmann, GA
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (03) : S312 - S316
  • [3] Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers
    Bradbury, Angela R.
    Ibe, Comfort. N.
    Dignam, James J.
    Cummings, Shelly A.
    Verp, Marion
    White, Melody A.
    Artioli, Grazia
    Dudlicek, Laura
    Olopade, Olufunmilayo L.
    [J]. GENETICS IN MEDICINE, 2008, 10 (03) : 161 - 166
  • [4] Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
    Buys, Saundra S.
    Partridge, Edward
    Black, Amanda
    Johnson, Christine C.
    Lamerato, Lois
    Isaacs, Claudine
    Reding, Douglas J.
    Greenlee, Robert T.
    Yokochi, Lance A.
    Kessel, Bruce
    Crawford, E. David
    Church, Timothy R.
    Andriole, Gerald L.
    Weissfeld, Joel L.
    Fouad, Mona N.
    Chia, David
    O'Brien, Barbara
    Ragard, Lawrence R.
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hartge, Patricia
    Pinsky, Paul F.
    Zhu, Claire S.
    Izmirlian, Grant
    Kramer, Barnett S.
    Miller, Anthony B.
    Xu, Jian-Lun
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2295 - 2303
  • [5] Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review
    Chen, F.
    Gaitskell, K.
    Garcia, M. J.
    Albukhari, A.
    Tsaltas, J.
    Ahmed, A. A.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 124 (06) : 872 - 878
  • [6] Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence
    Collaborative Group on Hormonal Factors in Breast Cancer
    [J]. LANCET, 2019, 394 (10204) : 1159 - 1168
  • [7] NCCN Guidelines® Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates to the NCCN Guidelines
    Daly, Mary B.
    Pilarski, Robert
    Berry, Michael
    Buys, Saundra S.
    Farmer, Meagan
    Friedman, Susan
    Garber, Judy E.
    Kauff, Noah D.
    Khan, Seema
    Klein, Catherine
    Kohlmann, Wendy
    Kurian, Allison
    Litton, Jennifer K.
    Madlensky, Lisa
    Merajver, Sofia D.
    Offit, Kenneth
    Pal, Tuya
    Reiser, Gwen
    Shannon, Kristen Mahoney
    Swisher, Elizabeth
    Vinayak, Shaveta
    Voian, Nicoleta C.
    Weitzel, Jeffrey N.
    Wick, Myra J.
    Wiesner, Georgia L.
    Dwyer, Mary
    Darlow, Susan
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (01): : 9 - 19
  • [8] Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
    Domchek, Susan M.
    Friebel, Tara M.
    Singer, Christian F.
    Evans, D. Gareth
    Lynch, Henry T.
    Isaacs, Claudine
    Garber, Judy E.
    Neuhausen, Susan L.
    Matloff, Ellen
    Eeles, Rosalind
    Pichert, Gabriella
    Van T'veer, Laura
    Tung, Nadine
    Weitzel, Jeffrey N.
    Couch, Fergus J.
    Rubinstein, Wendy S.
    Ganz, Patricia A.
    Daly, Mary B.
    Olopade, Olufunmilayo I.
    Tomlinson, Gail
    Schildkraut, Joellen
    Blum, Joanne L.
    Rebbeck, Timothy R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (09): : 967 - 975
  • [9] Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study
    Falconer, Henrik
    Yin, Li
    Gronberg, Henrik
    Altman, Daniel
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02):
  • [10] The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation
    Finch, A.
    Metcalfe, K. A.
    Chiang, J. K.
    Elit, L.
    McLaughlin, J.
    Springate, C.
    Demsky, R.
    Murphy, J.
    Rosen, B.
    Narod, S. A.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : 163 - 168